Observational studyNeurology2026
Sustained Benefits of a Multidomain Lifestyle Intervention in Multiple Sclerosis in the LIMS Study: A 24-Month Follow-Up.
Observational study in Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05402501 (Lifestyle Intervention for Patients With Multiple Sclerosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Lifestyle Intervention for Patients With Multiple Sclerosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesMultiple sclerosis (MS) often leads to physical, cognitive, and psychological impairments substantially affecting daily functioning and quality of life. Because current disease-modifying therapies do not fully prevent disease progression, interest has grown in the potential role of modifiable lifestyle factors. We evaluated (1) whether effects on patient-reported outcomes were sustained up to 24 months and (2) long-term changes in lifestyle behaviors after completion of the lifestyle in MS program.
methodsPeople with MS participated in a 3-month multimodal lifestyle program (i.e., Mediterranean-style diet, physical activity, and sleep and stress), followed by a 21-month maintenance phase. Patient-reported outcomes were assessed 3 months before the intervention, at baseline, postintervention, and after 6, 12, 18, and 24 months. The primary outcome was MS-related impact on daily functioning (MS Impact Scale-29 [MSIS-29]). Secondary outcomes included quality of life, general health, and MS-related symptoms. Longitudinal changes were analyzed using piecewise mixed-effects models, and individual-level change was evaluated using proportions exceeding the smallest detectable change (SDC).
resultsIn total, 659 participants were included (mean age 46 years, SD 11; 84% female). During the intervention phase, MSIS-29 physical and psychological scores significantly decreased by approximately 0.8 and 1.1 points per month, respectively, followed by attenuation during long-term follow-up. This was reflected by within-group changes of -2.7 (-3.7; -1.8) and -3.7 (-4.8; -1.6) points after the intervention and -0.8 (-1.7; 0.3) and -3.4 (-4.6; -2.3) point at month 24, remaining significantly improved or stable relative to baseline. Only a small proportion of participants exceeded the SDC for MSIS-29 (approximately 4%-7%). Trajectories were broadly similar across other patient-reported outcomes, with modest short-term improvements and subsequent stabilization. Most pronounced effects were found for dietary adherence and body mass index, which improved substantially during the intervention and remained partially sustained during follow-up. No significant changes were observed in physical activity adherence. DISCUSSION: In this large, real-world study, a digital multimodal lifestyle intervention was associated with modest, mainly short-term improvements in patient-reported outcomes and more pronounced individual-level changes in dietary behavior and body composition. These findings support a complementary role for lifestyle interventions in long-term MS management. TRIAL REGISTRATION INFORMATION: The study was registered at ClinicalTrials.gov (Identifier: NCT05402501; classic.clinicaltrials.gov/ct2/show/NCT05402501).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.